Search Results - "Spaans, E"

Healthcare reimbursement costs of children with type 1 diabetes in the Netherlands, a observational nationwide study (Young Dudes-4) by Spaans, E A J M, van Dijk, P R, Groenier, K H, Brand, P L P, Kleefstra, N, Bilo, H J G

“…Type 1 diabetes mellitus (T1DM) is one of the most common chronic diseases in children. Studies on costs related to T1DM are scarce and focused primarily on…”
Get full text

Adverse events of haloperidol for the treatment of delirium in critically ill children by Slooff, V. D., Spaans, E., van Puijenbroek, E., Jessurun, N., van Beusekom, B. S., de Hoog, M., Tibboel, D., de Wildt, S. N.

Get full text

Metabolism and Excretion of Asenapine in Healthy Male Subjects by VAN DE WETERING-KREBBERS, S. F. M, JACOBS, P. L, KEMPERMAN, G. J, SPAANS, E, PEETERS, P. A. M, DELBRESSINE, L. P. C, VAN LERSEL, M. L. P. S

“…The metabolism and excretion of asenapine [(3aRS,12bRS)-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]-oxepino [4,5-c]pyrrole (2Z)-2-butenedioate…”
Get full text

P.2.d.011 Low dose pipamperone, enhancing antidepressant effect of citalopram, occupies 5HT2A 50–60% leaving D2 nearly drug free by Buntinx, E, Bol, K, van den Berg, P, Spaans, E, Haazen, L

Get full text

Reliability and validity of the Dutch‐language version of the Viking Speech Scale in children with cerebral palsy by Spaans, Irene E. M., Geytenbeek, Joke J. M., Vaillant, Emma, Kleijn, Maaike A. M. C., Buizer, Annemieke I., Pennington, Lindsay

“…Purpose The Viking Speech Scale is used to classify speech performance in children with cerebral palsy (CP). A Dutch‐language version (VSS‐NL) has recently…”
Get full text

P.3.d.008 Asenapine pharmacokinetics: influence of cytochrome p450 modulators and udp-glucuronyltransferase inhibition by Dogterom, P, Hulskotte, E, Gerrits, M, Timmer, C, Ad Sitsen, J.M, de Greef, H, Spaans, E, Peeters, P

Get full text

Concomitant use of mirtazapine and phenytoin: a drug-drug interaction study in healthy male subjects by Spaans, E, van den Heuvel, M W, Schnabel, P G, Peeters, P A M, Chin-Kon-Sung, U G, Colbers, E P H, Sitsen, J M A

“…The objectives of this study were to assess the effect of mirtazapine on steady-state pharmacokinetics of phenytoin and vice versa and to assess tolerability…”
Get full text

Evaluation of the use of a medication database as a tool for detecting drug interactions by Spaans, E., Jansen, P. A. F.

“…At the department of geriatrics, medication is prescribed using a computerised system. The system includes a database on which the medication history of the…”
Get full text

A TEST OF THE RADIATIVE ENERGY BALANCE OF THE SHAW MODEL FOR SNOWCOVER by FLERCHINGER, G. N., BAKER, J. M., SPAANS, E. J. A.

“…Snow and ice present interesting challenges to hydrologists. Simulating the radiative balance over snow, which is an important part of surface–atmosphere…”
Get full text

Non-professional paint stripping, model prediction and experimental validation of indoor dichloromethane levels by Van Veen, M. P., Fortezza, F., Spaans, E., Mensinga, T. T.

“…We have experimentally quantified exposure to dichloromethane during non-professional paint stripping and validated the mathematical paint exposure model of…”
Get full text

Community Service in the Netherlands: Its Effects on Recidivism and Net-Widening by Spaans, E. C.

“…Community service was introduced in the Netherlands in 1981 in an effort to reduce the use of short-term imprisonment. Following the successful example of…”
Get full text

O-030 New Ibuprofen Dosing Strategy For Optimal Patent Ductus Arteriosus Closure In Preterm Neonates: Abstract O-030 Table 1 by Simons, SHP, Spaans, E, Reiss, IKM, Allegaert, K, Knibbe, CA

Get full text

O-030New Ibuprofen Dosing Strategy For Optimal Patent Ductus Arteriosus Closure In Preterm Neonates by Simons, SHP, Spaans, E, Reiss, IKM, Allegaert, K, Knibbe, CA

“…Background and aimsIbuprofen is the drug of first choice to close a patent ductus arteriosus (PDA) in preterm neonates. The most commonly used 10-5-5…”
Get full text

O-030 New Ibuprofen Dosing Strategy For Optimal Patent Ductus Arteriosus Closure In Preterm Neonates by Simons, SHP, Spaans, E, Reiss, IKM, Allegaert, K, Knibbe, CA

“…Background and aimsIbuprofen is the drug of first choice to close a patent ductus arteriosus (PDA) in preterm neonates. The most commonly used 10–5–5…”
Get full text

New ibuprofen dosing strategy for optimal patent ductus arteriosus closure in preterm neonates by Simons, SHP, Spaans, E, Reiss, IKM, Allegaert, K, Knibbe, CA

Get full text

O30 A comprehensive analysis of ontogeny of renal drug transporters: mRNA analyses, quantitative proteomics and localization by Cheung, KWK, van Groen, BD, Spaans, E, van Borselen, MD, Bruijn, ACJM de, Simons-Oosterhuis, Y, Tibboel, D, Samsom, JN, Verdijk, RM, Smeets, B, Zhang, L, Huang, S-M, Giacomini, KM, de Wildt, SN

“…BackgroundPostnatal developmental changes of human renal membrane transporters, which are key players of disposition of renally cleared drugs and endogenous…”
Get full text

Satisfaction, Happiness and Well-Being of Dutch Students by Vermunt, R., Spaans, E., Zorge, F.

“…Applying Multiple Discrepancies Theory (MDT), the well-being of Dutch students was measured. To test relevant portions of MDT a questionnaire, originally…”
Get full text

Lead toxicokinetics. Development of a biokinetic model to understand and predict the outcome of treatment by de Vries, I, Spaans, E, van Dijk, A, Meulenbelt, J

“…Quite often physicians contact the Dutch Poisons Control Centre for information on patients with increased lead exposure. The most important questions raised…”
Get more information

The soil freezing characteristic: its measurement and similarity to the soil moisture characteristic by Spaans, E.J.A. (Univ. of Minnesota, St. Paul, MN.), Baker, J.M

“…A soil freezing characteristic (SFC) represents the relationship between the quantity and the energy status of liquid water in frozen soil. The SFC is the…”
Get full text

Concomitant Use of Gepirone-er and Lithium: An Interaction Study by Spaans, E., Timmer, C.J., Machielsen, C.S.M., Grzegorzewski, M.

“…Clinical Pharmacology & Therapeutics (2003) 73, P81–P81; doi:…”
Get full text